Table 2.
Change in Sensitivity, Specificity, and Predictive Values of Pretreatment and Posttreatment HPV-16 Status Under Different Detection Source
| Detection Source | Sensitivity, % | Specificity, % | PPV, % | NPV, % |
|---|---|---|---|---|
| Pretreatmenta | ||||
| Saliva only | 52.8 | 100 | 100 | 24.4 |
| Plasma only | 67.3 | 100 | 100 | 34.6 |
| Combined | 76.1 | 100 | 100 | 42.1 |
| Posttreatmentb | ||||
| Saliva only | 18.8 | 96.6 | NA | NA |
| Plasma only | 55.1 | 95.6 | NA | NA |
| Combined | 69.5 | 90.7 | NA | NA |
Abbreviations: HPV, human papillomavirus; NA, not applicable; NPV, negative predictive value; PPV, positive predictive value.
a
Clinical outcome: tumor HPV status.
b
Clinical outcome: tumor recurrence within 3 years among patients with HPV-16-positive tumors.